|
Vaccine Detail
C. abortus DNA vaccine encoding GatA/GatB |
Vaccine Information |
- Vaccine Name: C. abortus DNA vaccine encoding GatA/GatB
- Target Pathogen: Chlamydophila abortus
- Target Disease: Abortion and fetal death
- Vaccine Ontology ID: VO_0011520
- Type: DNA vaccine
- Status: Research
- Antigen: C. abortus Glu-tRNA Gln Amidotransferase gatA and gatB
- gatA
gene engineering:
- Type: DNA vaccine construction
- Description: To create the library of genetic immunization plasmids, genomic DNA of C. abortus strain B577 was physically sheared and cloned into the genetic immunization vector pCMVi-UB, which drives transcription using the strong mammalian CMV promoter (Stemke-Hale et al., 2005).
- Detailed Gene Information: Click Here.
- gatB
gene engineering:
- Type: DNA vaccine construction
- Description: To create the library of genetic immunization plasmids, genomic DNA of C. abortus strain B577 was physically sheared and cloned into the genetic immunization vector pCMVi-UB, which drives transcription using the strong mammalian CMV promoter (Stemke-Hale et al., 2005).
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0005027
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Mouse Response
- Host Strain: BALB/c
- Vaccination Protocol: Doses of 50 μg library DNA were delivered intramuscularly to the quadriceps and tibialis anterior muscles. Doses of 2.5 μg DNA were delivered to the ear skin of mice with a gene gun. C. abortus B577 was grown in BGMK cells and titrated for IFU in BGMK shell vial coverslip cultures by enumeration of chlamydial inclusions stained with FITC-labeled monoclonal antibody against chlamydial LPS. For rounds 1 and 2 of ELI, mice were boosted 9 weeks after the prime inoculation in the same manner, and for rounds 3 and 4 of ELI the mice were given an additional boost 5 weeks after the prime (Stemke-Hale et al., 2005).
- Challenge Protocol: In all cases, mice were challenged at 13 weeks with a dose of 3 × 10^6 inclusion forming units (IFU) of C. abortus administered intranasally. The positive control group representing protection received a low dose intranasal inoculation of 3 × 10^4 IFU of the same live strain four weeks prior to the high-dose challenge (Stemke-Hale et al., 2005).
- Efficacy: Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #3, gatA/gatB) was found to be protective. Three of the clones (CP #1–3) elicited protection that was statistically higher than the unvaccinated control, which has high variance (Stemke-Hale et al., 2005).
|
References |
Stemke-Hale et al., 2005: Stemke-Hale K, Kaltenboeck B, DeGraves FJ, Sykes KF, Huang J, Bu CH, Johnston SA. Screening the whole genome of a pathogen in vivo for individual protective antigens. Vaccine. 2005; 23(23); 3016-3025. [PubMed: 15811648].
|
|